Formulation strategy and optimization of cinnarizine -encapsulated microspheres
Keywords:
PLGA, Chitosan, Microspheres, solvent evaporationAbstract
Cinnarizine is an active histamine analog primarily used in the treatment of vertigo, tinnitus, and Meniere's disease—conditions related to vestibular disorders and inner ear dysfunction. However, Cinnarizine’s clinical efficacy is hindered by its short half-life, rapid clearance, and limited oral bioavailability. Polymeric microspheres, especially those made from biodegradable materials such as Poly (lactic-co-glycolic acid) (PLGA) and Chitosan, have shown considerable potential for controlled drug release. The current research work focused on the preparation and optimization of Cinnarizine microspheres, which can be scaled up and used commercially in future.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Advances in Pharmaceutics
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).